ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 813

Long-Term Outcomes of Takayasu’s Arteritis Patients with Renal Artery Involvement

Corisande Baldwin1, Aladdin Mohammad2 and David Jayne3, 1Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2Dept. of Rheumatology, Lund University Hospital, Lund University, Lund, Lund, Sweden, 3Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: outcomes, Renal disease, takayasu arteritis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Takayasu’s Arteritis (TAK) is a chronic inflammatory large vessel vasculitis characterized by granulomatous inflammation of the aorta and its branches. TAK incidence is 2.6/million annually in Minnesota. Prevalence is higher in Asian and Indian populations. TAK predominantly affects younger woman under 40 years of age. Renal artery involvement (RAI) in TAK is a poor prognostic factor. However, long-term outcomes of TAK patients with RAI have not been reported.

Methods: We performed a retrospective chart review of 37 patients from Addenbrooke’s Hospital, UK, and 13 patients from Skane University Hospital, Sweden. Diagnosis of TAK was based on the presence of constitutional symptoms, elevated inflammatory markers, and vascular abnormalities on angiography. RAI was identified based on conventional, CT or MR angiography. Data was collected on patient demographics and presenting symptoms, signs, co-morbidities, blood pressure and medications. Laboratory values including creatinine, erythrocyte sedimentation rate, and c-reactive protein were collected. Disease activity was assessed using the Indian Takayasu Activity Index 2010 (ITAS2010). Irreversible organ damage was assessed using the vasculitis damage index (VDI). Worsening or improved renal function was defined as a drop or increase in eGFR > 20%.

Results: Sixteen of 50 (32%) TAK patients were identified to have RAI. Presenting demographics and disease parameters are summarized in Table 1. Two patients had structural renal disease (PUJ obstruction and prior renal surgery undefined) and are among the 7 patients with renal asymmetry; one was among the nine patients with pre-existing hypertension. The three with eGFR <60 ml/min had moderate renal dysfunction (eGFRs of 45, 57, and 59 ml/min).

Follow-up data is presented in Table 2. Median follow-up duration was 8.8 years (10 months – 30 years). Among the 13 with hypertension including two who developed hypertension over the follow-up period; 11 were on anti-hypertensive drugs. Among the six patients with renal asymmetry; five were known and one developed this over the follow-up period. Among those with eGFR < 60 ml/min at presentation, one improved, one declined (patient with PUJ obstruction), and one remained stable.

Conclusion: The prevalence of RAI in this population (32%) is comparable to that in the literature. Hypertension was common. Most patients had normal eGFRs, despite severe disease. Disease progression was minimal. Our results suggest renal prognosis is better than previously thought.


Disclosure:

C. Baldwin,
None;

A. Mohammad,
None;

D. Jayne,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-outcomes-of-takayasus-arteritis-patients-with-renal-artery-involvement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology